You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
Express Scripts
Harvard Business School
Mallinckrodt

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,246,979


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,246,979 protect, and when does it expire?

Patent 8,246,979 protects NEUPRO and is included in one NDA.

This patent has twenty-seven patent family members in nineteen countries.

Summary for Patent: 8,246,979
Title:Transdermal delivery system for the administration of rotigotine
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/623,864
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,246,979
Patent Claim Types:
see list of patent claims
Delivery; Use;

Drugs Protected by US Patent 8,246,979

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No   Start Trial   Start Trial Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM   Start Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No   Start Trial   Start Trial Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM   Start Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM   Start Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM   Start Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No   Start Trial   Start Trial Y TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM   Start Trial
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No   Start Trial   Start Trial Y TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,246,979

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02016860Jul 30, 2002

International Family Members for US Patent 8,246,979

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 322263   Start Trial
Australia 2003258539   Start Trial
Brazil 0313091   Start Trial
Canada 2491366   Start Trial
China 101953819   Start Trial
China 1671375   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Mallinckrodt
Moodys
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.